WESTMINSTER, Colo.-- Allos Therapeutics, Inc. announced the presentation of updated safety results from its Phase 1/2 trial of PDX (pralatrexate) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease.
PDX is a dihydrofolate reductase inhibitor, a folic acid dependent enzyme that is essential in the replication of DNA in rapidly proliferating cells. Inhibiting DHFR has been drug targets in biopharmaceutical companies for a long time being targets of bacterial infections, cancer, viral infections and so on.
Allos Therapeutics is up ~16% to $5.75 in afternoon heavy trading. The stock was also recently up-graded to "buy" by Reit.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment